Trials / Completed
CompletedNCT01746680
Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis
Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The aims of this study are to assess the efficacy and safety of tacrolimus in patients with active rheumatoid arthritis(RA). EULAR(European League Against Rheumatism) response at week 24 compared to baseline will be evaluated to assess the efficacy of Tacrolimus.
Detailed description
A Phase IV, Open labeled, Multi-Center Trial to Assess the Efficacy and Safety of Tacrolimus(Tacrobell®)in patients with active rheumatoid arthritis(RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tacrolimus with Methotrexate | Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2012-12-11
- Last updated
- 2015-08-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01746680. Inclusion in this directory is not an endorsement.